President-elect Donald Trump’s decision to nominate Robert F. Kennedy Jr. as Secretary of Health and Human Services (HHS) is causing unease among pharmaceutical companies, given Kennedy’s past advocacy for banning pharmaceutical advertising.
If confirmed by the Senate, Kennedy would have the authority to direct public health agencies in alignment with hi…
Listen to this episode with a 7-day free trial
Subscribe to "Relentless" Newsletter to listen to this post and get 7 days of free access to the full post archives.
